Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
BeiGene, Ltd. | CMO, Hematology | Ordinary Shares | 160K | $33.2M | $207.72 | Dec 14, 2021 | Direct |
Prelude Therapeutics Inc | President, CMO | Restricted Stock Unit | 65.6K | $311K | $4.74 | Jul 4, 2024 | Direct |
Prelude Therapeutics Inc | President, CMO | Common Stock | 63.3K | $127K | $2.00 | Oct 4, 2024 | Direct |
BeiGene, Ltd. | CMO, Hematology | Share Option (Right to Buy) | 211K | Dec 14, 2021 | Direct | ||
Prelude Therapeutics Inc | President, CMO | Employee Stock Option (right to buy) | 175K | Mar 1, 2024 | Direct | ||
Prelude Therapeutics Inc | President, CMO | Restricted Stock Unit | 56.3K | Oct 4, 2024 | Direct | ||
Protara Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 10K | Jun 7, 2024 | Direct | ||
BeiGene, Ltd. | CMO, Hematology | American Depositary Shares | 0 | $180.50 | Dec 14, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
PRLD | Prelude Therapeutics Inc | Oct 4, 2024 | 3 | -$6.7K | 4 | Oct 7, 2024 | President, CMO |
PRLD | Prelude Therapeutics Inc | Jul 4, 2024 | 3 | -$12K | 4 | Jul 8, 2024 | President, CMO |
TARA | Protara Therapeutics, Inc. | Jun 7, 2024 | 1 | $0 | 4 | Jun 10, 2024 | Director |
PRLD | Prelude Therapeutics Inc | Apr 4, 2024 | 3 | -$15.9K | 4 | Apr 8, 2024 | President, CMO |
PRLD | Prelude Therapeutics Inc | Mar 1, 2024 | 1 | $0 | 4 | Mar 4, 2024 | President, CMO |
PRLD | Prelude Therapeutics Inc | Jan 4, 2024 | 3 | -$14.5K | 4 | Jan 8, 2024 | President, CMO |
PRLD | Prelude Therapeutics Inc | Oct 4, 2023 | 2 | $0 | 4 | Oct 6, 2023 | President, CMO |
PRLD | Prelude Therapeutics Inc | Jul 4, 2023 | 3 | -$15.1K | 4 | Jul 6, 2023 | President, CMO |
TARA | Protara Therapeutics, Inc. | Jun 7, 2023 | 1 | $0 | 4 | Jun 8, 2023 | Director |
PRLD | Prelude Therapeutics Inc | Apr 4, 2023 | 3 | -$81.3K | 4 | Apr 6, 2023 | President, CMO |
PRLD | Prelude Therapeutics Inc | Feb 7, 2023 | 1 | $0 | 4 | Feb 9, 2023 | President, CMO |
TARA | Protara Therapeutics, Inc. | Jun 8, 2022 | 1 | $0 | 4 | Jun 9, 2022 | Director |
PRLD | Prelude Therapeutics Inc | May 2, 2022 | 2 | $0 | 4 | May 4, 2022 | President, CMO |
PRLD | Prelude Therapeutics Inc | Apr 4, 2022 | 0 | $0 | 3 | Apr 6, 2022 | President, CMO |
BGNE | BeiGene, Ltd. | Dec 14, 2021 | 8 | -$237K | 4 | Dec 16, 2021 | CMO, Hematology |
BGNE | BeiGene, Ltd. | Nov 30, 2021 | 4 | -$377K | 4 | Dec 2, 2021 | CMO, Hematology |
BGNE | BeiGene, Ltd. | Nov 17, 2021 | 11 | -$392K | 4 | Nov 19, 2021 | CMO, Hematology |
BGNE | BeiGene, Ltd. | Oct 19, 2021 | 9 | -$379K | 4 | Oct 21, 2021 | CMO, Hematology |
BGNE | BeiGene, Ltd. | Sep 20, 2021 | 16 | -$1.67M | 4 | Sep 22, 2021 | CMO, Hematology |
BGNE | BeiGene, Ltd. | Sep 13, 2021 | 8 | -$4.62M | 4 | Sep 15, 2021 | CMO, Hematology |
BGNE | BeiGene, Ltd. | Aug 31, 2021 | 6 | -$347K | 4 | Sep 2, 2021 | CMO, Hematology |
BGNE | BeiGene, Ltd. | Jul 15, 2021 | 12 | -$3.9M | 4 | Jul 19, 2021 | CMO, Hematology |
BGNE | BeiGene, Ltd. | Jun 28, 2021 | 9 | -$639K | 4 | Jun 30, 2021 | CMO, Hematology |
BGNE | BeiGene, Ltd. | Jun 16, 2021 | 3 | -$153K | 4 | Jun 21, 2021 | CMO, Hematology |
TARA | Protara Therapeutics, Inc. | Jun 9, 2021 | 2 | $0 | 4 | Jun 10, 2021 | Director |
TARA | Protara Therapeutics, Inc. | Jun 9, 2021 | 0 | $0 | 3 | Jun 10, 2021 | Director |
BGNE | BeiGene, Ltd. | Jun 7, 2021 | 1 | -$212K | 4 | Jun 9, 2021 | CMO, Hematology |
BGNE | BeiGene, Ltd. | May 28, 2021 | 11 | -$686K | 4 | Jun 2, 2021 | CMO, Hematology |